From NETTER to PETTER: PSMA-Targeted radioligand therapy

Matthias Eiber; Ken Herrmann

doi:10.2967/jnumed.116.184994

From NETTER to PETTER: PSMA-Targeted radioligand therapy

Matthias Eiber
, Ken Herrmann

Department of Nuclear Medicine

David Geffen School of Medicine at UCLA
University Hospital of Essen

Research output: Contribution to journal › Review article › peer-review

8 Scopus citations

Abstract

In this month's issue of The Journal of Nuclear Medicine, Rahbar et al. present exciting retrospective German multicenter data (12 centers) on the performance of prostate-specific membrane antigen (PSMA)-Targeted radioligand therapy (RLT) using ¹⁷⁷ Lu-PSMA 617 in metastatic castration-resistant prostate cancer (mCRPC) (1). The authors describe in detail the safety and efficacy of this new theranostic approach applied under the compassionate use provision in 145 patients.

Original language	English
Pages (from-to)	9-10
Number of pages	2
Journal	Journal of Nuclear Medicine
Volume	58
Issue number	1
DOIs	https://doi.org/10.2967/jnumed.116.184994
State	Published - 1 Jan 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.2967/jnumed.116.184994

Cite this

@article{d881cf83db5b482ab4d7bd520530eef5,

title = "From NETTER to PETTER: PSMA-Targeted radioligand therapy",

abstract = " In this month's issue of The Journal of Nuclear Medicine, Rahbar et al. present exciting retrospective German multicenter data (12 centers) on the performance of prostate-specific membrane antigen (PSMA)-Targeted radioligand therapy (RLT) using 177 Lu-PSMA 617 in metastatic castration-resistant prostate cancer (mCRPC) (1). The authors describe in detail the safety and efficacy of this new theranostic approach applied under the compassionate use provision in 145 patients.",

author = "Matthias Eiber and Ken Herrmann",

year = "2017",

month = jan,

day = "1",

doi = "10.2967/jnumed.116.184994",

language = "English",

volume = "58",

pages = "9--10",

journal = "Journal of Nuclear Medicine",

issn = "0161-5505",

publisher = "Society of Nuclear Medicine Inc.",

number = "1",

}

TY - JOUR

T1 - From NETTER to PETTER

T2 - PSMA-Targeted radioligand therapy

AU - Eiber, Matthias

AU - Herrmann, Ken

PY - 2017/1/1

Y1 - 2017/1/1

N2 - In this month's issue of The Journal of Nuclear Medicine, Rahbar et al. present exciting retrospective German multicenter data (12 centers) on the performance of prostate-specific membrane antigen (PSMA)-Targeted radioligand therapy (RLT) using 177 Lu-PSMA 617 in metastatic castration-resistant prostate cancer (mCRPC) (1). The authors describe in detail the safety and efficacy of this new theranostic approach applied under the compassionate use provision in 145 patients.

AB - In this month's issue of The Journal of Nuclear Medicine, Rahbar et al. present exciting retrospective German multicenter data (12 centers) on the performance of prostate-specific membrane antigen (PSMA)-Targeted radioligand therapy (RLT) using 177 Lu-PSMA 617 in metastatic castration-resistant prostate cancer (mCRPC) (1). The authors describe in detail the safety and efficacy of this new theranostic approach applied under the compassionate use provision in 145 patients.

UR - https://www.scopus.com/pages/publications/85009144621

U2 - 10.2967/jnumed.116.184994

DO - 10.2967/jnumed.116.184994

M3 - Review article

C2 - 27856632

AN - SCOPUS:85009144621

SN - 0161-5505

VL - 58

SP - 9

EP - 10

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

IS - 1

ER -

From NETTER to PETTER: PSMA-Targeted radioligand therapy

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this